Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - melphalan hydrochloride, quantity: 55.97 mg (equivalent: melphalan, qty 50 mg) - injection, powder for - excipient ingredients: hydrochloric acid; povidone - melphalan injection is indicated for the treatment of patients with multiple myeloma for whom oral therapy is not appropriate.

Canada - English - Health Canada

auro pharma inc - melphalan (melphalan hydrochloride) - kit - 50mg - melphalan (melphalan hydrochloride) 50mg - antineoplastic agents

Canada - English - Health Canada

eugia pharma inc. - melphalan (melphalan hydrochloride) - kit - 50mg - melphalan (melphalan hydrochloride) 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

aspen pharma trading ltd - melphalan hydrochloride - powder and solvent for solution for injection - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

aspen pharma trading ltd - melphalan - oral tablet - 2mg

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - melphalan - tablets - melphalan 2 mg - melphalan - melphalan - for the treatment of : multiple myeloma and advanced ovarian adenocarcinoma

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - melphalan - film-coated tablet - melphalan - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - melphalan hydrochloride, quantity: 55.97 mg (equivalent: melphalan, qty 50 mg) - injection, powder for - excipient ingredients: povidone; hydrochloric acid - melphalan injection is indicated for the treatment of patients with multiple myeloma for whom oral therapy is not appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - melphalan, quantity: 2 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - alkeran is indicated for the palliative treatment of multiple myeloma and advanced ovarian adenocarcinoma. alkeran has a significant therapeutic effect in a proportion of patients suffering from advanced breast carcinoma and may be used in the treatment of polycythaemia vera.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - melphalan, quantity: 50 mg - injection, powder for - excipient ingredients: povidone; hydrochloric acid - for the treatment of patients with multiple myeloma for whom oral therapy is not appropriate